Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-555 PET Study in Relapsing Multiple Sclerosis
NCT02606630Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elezanumab in multiple sclerosis (MS), sponsored by AbbVie Inc. Primary endpoint: Change in translocator protein expression at Day 109. Started Oct 2015; status: terminated.
02
Drugs
elezanumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02606630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606630.